Biotechnology Recombinant Protein Law In Russia.
1. Introduction
Biotechnology recombinant protein law in Russia concerns the legal regulation of producing, developing, testing, patenting, registering, manufacturing, distributing and commercialising proteins created through recombinant DNA technology.
Recombinant proteins are proteins produced by inserting a specific genetic sequence into a host organism or cell, which then expresses the desired protein. Common production systems include:
Escherichia coli (E. coli) bacteria.
Yeast cells.
Mammalian cell cultures.
Genetically modified plant cells.
Other engineered microorganisms.
Examples of recombinant protein products include:
Recombinant human insulin.
Human growth hormone.
Recombinant interferons.
Erythropoietin (EPO).
Recombinant blood-clotting factors.
Therapeutic enzymes.
Recombinant vaccines and antigen proteins.
Monoclonal antibodies and engineered protein therapeutics.
Russia does not have one separate statute exclusively governing recombinant proteins. Instead, several areas of law operate together, particularly pharmaceutical regulation, genetic engineering, intellectual property, industrial safety, clinical research and environmental protection.
The central objective is to balance biotechnology innovation with product quality, patient safety, scientific reliability and protection of intellectual property.
2. Principal Russian legislation
The following legislation provides the principal legal framework.
| Legislation | Legal significance |
|---|---|
| Federal Law No. 61-FZ of 2010 | Circulation and registration of medicinal products |
| Federal Law No. 86-FZ of 1996 | Genetic engineering activities |
| Civil Code, Part IV | Patents and intellectual property |
| Federal Law No. 52-FZ of 1998 | Sanitary and epidemiological protection |
| Federal Law No. 7-FZ of 2002 | Environmental protection |
| Federal Law No. 152-FZ of 2006 | Personal data protection |
| Federal Law No. 323-FZ of 2011 | Protection of public health and medical activities |
An additional important framework is the Eurasian Economic Union (EAEU) pharmaceutical regulatory system, which applies to Russia alongside its national legislation.
aipla.org+1
3. Regulation of genetic engineering activities
Federal Law No. 86-FZ of 5 July 1996, On State Regulation in the Field of Genetic Engineering Activities, is particularly important.
It regulates genetic-engineering activities involving recombinant DNA and RNA technologies and addresses environmental protection, biological safety and human health.
Its principal provisions include:
A. Article 1 – Scope of regulation
Establishes the scope of genetic-engineering regulation, including environmental and health-protection considerations.
B. Article 2 – Definitions
Provides definitions relating to genetic engineering, genetic information and genetically modified organisms.
C. Article 6 – Genetic engineering activities
Covers genetic manipulation at molecular and cellular levels using recombinant nucleic acids to create genetically modified organisms.
D. Article 7 – Biosafety
Establishes a biosafety framework, including risk assessment and protection of workers, the public and the environment.
E. Article 11 – Product compliance
Products obtained through genetic-engineering activities must comply with applicable environmental, pharmacopoeial, sanitary and other mandatory requirements.
F. Article 12 – Liability
Provides for legal responsibility where genetic-engineering activities cause harm or where applicable requirements governing the use of genetically modified organisms are violated.
Consultant Plus+3
Important legal distinction: A recombinant protein manufactured using genetically modified bacteria in a controlled industrial bioreactor is not automatically treated in the same way as a genetically modified organism deliberately released into the environment.
The regulatory classification depends on the actual production system, the product and its intended use. The environmental GMO-registration requirements must not be confused with medicinal-product registration.
4. Medicinal-product registration under Federal Law No. 61-FZ
Federal Law No. 61-FZ of 12 April 2010, On Circulation of Medicines, is central when recombinant proteins are intended for human therapeutic use.
The law regulates:
Drug development.
Preclinical research.
Clinical trials.
Scientific examination.
State registration.
Manufacturing.
Quality control.
Storage and transportation.
Import and export.
Distribution and sale.
Pharmacovigilance.
Article 1 establishes the broad scope of medicinal-product regulation, while Article 13 establishes the state-registration framework.
A recombinant protein cannot lawfully be marketed as an ordinary therapeutic medicine merely because its protein sequence has been successfully expressed in a laboratory.
It must satisfy the applicable regulatory requirements for safety, quality and efficacy.
CIS Legislation+1
5. EAEU regulatory framework for recombinant proteins
Russia is a member of the Eurasian Economic Union. Consequently, the EAEU medicinal-product framework is particularly important for recombinant biological medicines.
Three decisions deserve special attention.
EAEU Council Decision No. 78 of 3 November 2016
Medicinal-product registration
Establishes rules for registration and examination of medicinal products for medical use.
It governs registration dossiers, regulatory examination, amendments, re-registration and related procedures.
Official source: Eurasian Economic Commission – Decision No. 78
EAEU Council Decision No. 89 of 3 November 2016
Biological medicines
Establishes specific assessment rules for biological medicinal products.
It is relevant to recombinant proteins, therapeutic antibodies and other biological medicines.
Official source: Eurasian Economic Commission – Decision No. 89
EAEU Council Decision No. 77 of 3 November 2016
Good Manufacturing Practice
Approves the EAEU Good Manufacturing Practice (GMP) rules.
It establishes manufacturing-quality requirements applicable to biological medicinal products.
Official source: Eurasian Economic Commission – Decision No. 77
docs.eaeunion.org+2
6. Manufacturing requirements for recombinant proteins
Recombinant protein production involves several scientifically sensitive stages. Russian pharmaceutical regulation requires manufacturers to control the relevant manufacturing and quality processes.
The main stages are:
Gene selection: Selection and verification of the DNA sequence responsible for producing the target protein.
Vector construction: Preparation of a suitable recombinant expression vector.
Host-cell development: Selection and characterisation of the bacterial, yeast or mammalian production system.
Cell banking: Establishment and control of master and working cell banks.
Fermentation: Controlled cultivation and protein expression.
Protein recovery: Collection and separation of the expressed protein.
Purification: Removal of host-cell proteins, residual DNA, endotoxins and other impurities.
Protein characterisation: Assessment of molecular identity, structure and biological activity.
Formulation: Preparation of the final medicinal formulation.
Batch release: Quality assessment before the product enters commercial distribution.
Important quality-control requirements
| Quality parameter | Legal and regulatory importance |
|---|---|
| Identity | Confirms the correct recombinant protein |
| Purity | Controls unwanted protein impurities |
| Potency | Establishes biological activity |
| Stability | Determines product shelf life |
| Endotoxin levels | Controls bacterial contamination risks |
| Host-cell proteins | Controls process-related impurities |
| Residual DNA | Controls manufacturing-related contamination |
| Sterility | Protects patients from microbial contamination |
| Immunogenicity | Assesses potentially harmful immune responses |
For example, recombinant human insulin must be appropriately characterised to establish that its identity, purity, potency and safety meet the applicable quality requirements.
7. Clinical trials and scientific evidence
Recombinant protein medicines may require preclinical and clinical investigation before registration.
Clinical development generally involves:
Laboratory and preclinical evaluation.
Initial human safety studies.
Dose and pharmacological assessment.
Therapeutic efficacy studies.
Safety monitoring.
Evaluation of adverse reactions.
Assessment of benefit-risk balance.
The EAEU framework also includes Good Clinical Practice requirements under Council Decision No. 79 of 3 November 2016.
The scientific evidence must establish that the product is sufficiently characterised and suitable for its proposed medical use.
A manufacturer cannot substitute a successful laboratory expression experiment for the clinical and regulatory evidence required for a therapeutic medicine.
8. Biosimilars and recombinant protein medicines
One of the most important legal questions concerns biosimilar medicines.
A biosimilar is a biological medicine containing a version of the active ingredient of an already registered reference biological medicine, for which similarity has been demonstrated through appropriate comparative studies.
For example:
A biosimilar insulin product compared with reference insulin.
A biosimilar erythropoietin product.
A biosimilar recombinant growth hormone.
A biosimilar therapeutic antibody.
Under the EAEU registration rules, biosimilarity is not established merely by showing that two medicines have the same amino-acid sequence.
The manufacturer must provide appropriate comparative evidence concerning:
Structural characteristics.
Biological activity.
Quality attributes.
Impurity profiles.
Safety.
Clinical efficacy.
Immunogenicity.
The extent of comparative nonclinical and clinical studies depends on the product and the applicable regulatory requirements.
Legal significance: A biosimilar is not automatically identical to its reference medicine in every manufacturing-related characteristic. Differences in expression systems, glycosylation and other critical quality attributes may require scientific evaluation.
ealegislation.com+1
9. Patent protection of recombinant proteins
Patent protection is another major component of Russian recombinant protein law.
Part IV of the Russian Civil Code regulates intellectual property.
Relevant provisions include:
| Civil Code provision | Subject |
|---|---|
| Article 1349 | Patentable subject matter and exclusions |
| Article 1350 | Patentability of inventions |
| Article 1354 | Scope of patent protection |
| Article 1356 | Right of authorship |
| Article 1358 | Use of patented inventions |
| Article 1398 | Invalidity of patents |
A recombinant protein-related invention may potentially receive patent protection where the statutory requirements are satisfied.
Examples include:
A novel engineered protein.
A new amino-acid sequence.
A recombinant production strain.
A novel expression vector.
An improved purification process.
A pharmaceutical composition.
A technically supported manufacturing method.
Three basic patentability requirements are particularly important:
Novelty: The invention must not already be disclosed in the relevant prior art.
Inventive step: The technical solution must not be obvious to a person skilled in the relevant field.
Industrial applicability: The invention must be capable of practical industrial use.
A naturally occurring protein is not automatically patentable simply because researchers have discovered it. The precise claimed technical invention and statutory exclusions must be examined.
10. Important Russian cases and legal precedents
Russia has a relatively limited body of reported court judgments specifically concerning recombinant protein production. However, patent proceedings involving engineered microorganisms and pharmaceutical patent disputes provide useful legal guidance.
The following authorities should be distinguished according to whether they are court judgments or administrative patent decisions.
Case 1. GEROPHARM – Escherichia coli recombinant insulin patent dispute (2025)
Direct biotechnology-related proceeding
Patent: Russian Patent No. 2807548.
Patent holder: GEROPHARM LLC (ГЕРОФАРМ).
Administrative authority: Rospatent, Chamber for Patent Disputes.
Proceeding: Application No. 2023124743/63.
Hearing: 13 August 2025.
Decision approved: 13 October 2025.
Facts
The patent concerned an engineered Escherichia coli strain with reduced acetate accumulation, designed to produce a hybrid polypeptide containing insulin glargine proinsulin.
The invention involved a bacterial strain identified as E. coli BL21-74/pF644.
The patent challenger questioned whether the patent sufficiently disclosed how the invention could be implemented. The challenge also raised questions about industrial applicability and inventive step.
Legal questions
Was the invention sufficiently disclosed?
Could the bacterial strain actually produce the intended protein?
Was there sufficient technical evidence of industrial applicability?
Did the claimed invention involve an inventive step?
Was the relationship between the production strain and the final pharmaceutical composition adequately established?
Outcome
Rospatent rejected the challenge and maintained Russian Patent No. 2807548 in force.
Legal significance
This proceeding is particularly important because it concerns the relationship between:
Genetically engineered bacterial strains.
Recombinant insulin production.
Technical disclosure.
Protein-expression technology.
Industrial applicability.
Pharmaceutical applications of recombinant proteins.
It illustrates that biotechnology patent claims must be supported by an adequate technical description of the claimed invention.
Important qualification: This was an administrative patent-validity proceeding, not a court judgment.
ГАРАНТ+1
Case 2. Supreme Court of Russia – Unregistered genetically modified rapeseed (2023)
Supreme Court judgment
Court: Supreme Court of the Russian Federation.
Case No.: 9-АД23-12-К1.
Decision date: 19 September 2023.
Relevant legislation: Federal Law No. 86-FZ and Article 6.3.1 of the Code of Administrative Offences.
Facts
The case concerned the use of genetically modified rapeseed containing the CP4 EPSPS genetic element.
Agricultural inspections identified the use of genetically modified seeds without the required registration.
The company was fined RUB 250,000.
Legal issue
Whether the use of genetically modified organisms without the required state registration constituted an administrative violation.
Decision
The Supreme Court upheld the earlier decisions and confirmed the administrative liability.
Legal significance for recombinant protein biotechnology
Although this dispute concerned genetically modified agricultural organisms rather than therapeutic proteins, it demonstrates that:
Genetic-engineering activities are subject to statutory controls.
Registration obligations must be respected where applicable.
Technical evidence can establish the presence of genetically modified material.
Companies may face administrative penalties for non-compliance.
The judgment is relevant to recombinant protein manufacturers where their activities involve regulated GMO use, particularly environmental release.
However, it does not establish that every contained recombinant protein manufacturing process requires environmental GMO registration.
ГАРАНТ+1
Case 3. Nativa LLC v. Celgene Corporation – Lenalidomide patent dispute (2017–2019)
Court: Moscow Arbitration Court.
Case No.: A40-71471/2017.
Subject: Pharmaceutical patent protection and compulsory licensing.
Relevant law: Article 1362 of the Russian Civil Code.
Facts
Nativa sought a compulsory non-exclusive licence relating to Celgene's patent for lenalidomide.
The dispute involved patent exclusivity, pharmaceutical market access and the statutory conditions for compulsory licensing.
Legal significance
The case illustrates that patent protection in the pharmaceutical sector must be considered alongside the statutory mechanism for compulsory licensing.
The patent was subsequently challenged and invalidated in administrative proceedings, and the compulsory-licensing arrangement was eventually annulled.
Relevance to recombinant proteins
A manufacturer of recombinant insulin, therapeutic enzymes or other patented biological medicines must consider:
Patent ownership.
Existing patent licences.
Patent validity.
Compulsory-licensing requirements.
Commercial freedom to operate.
This is an analogous pharmaceutical patent precedent, not a direct recombinant protein judgment.
Law Gratis+1
Case 4. Sugen LLC and Pharmacia & Upjohn v. Nativa LLC (2017–2020)
Case No.: A40-166505/2017.
Subject: Pharmaceutical patent infringement and compulsory licensing.
Relevant law: Article 1362 of the Civil Code.
Legal questions
The proceedings concerned patent exclusivity and the circumstances in which a pharmaceutical manufacturer could obtain a compulsory licence.
Legal significance
The litigation demonstrates that pharmaceutical companies must independently assess patent rights and possible compulsory-licensing exposure.
For recombinant protein manufacturers, the same issues may arise when producing patented therapeutic proteins, production methods or pharmaceutical formulations.
This case is also an analogous pharmaceutical dispute rather than a direct recombinant protein judgment.
Law Gratis+1
11. Regulatory authorities responsible for recombinant protein regulation
Several Russian institutions have responsibilities relevant to recombinant protein research and commercialisation.
| Authority | Principal responsibility |
|---|---|
| Ministry of Health of Russia | Pharmaceutical policy and regulatory administration |
| Roszdravnadzor | Healthcare and medicinal-product supervision |
| Rospotrebnadzor | Sanitary and epidemiological supervision |
| Rospatent | Patent registration and intellectual property |
| Ministry of Industry and Trade | Industrial development and pharmaceutical manufacturing policy |
| Ministry of Natural Resources | Environmental regulatory matters |
| Federal Service for Veterinary and Phytosanitary Surveillance | Relevant agricultural and veterinary GMO oversight |
The Eurasian Economic Commission also has an important role in developing and administering the common pharmaceutical regulatory framework.
12. Product liability and patient protection
Recombinant protein manufacturers may face liability when defective products cause injury.
Potential problems include:
Incorrect protein folding.
Contamination during manufacturing.
Excessive endotoxin levels.
Incorrect dosage.
Reduced biological potency.
Unexpected immune reactions.
Inadequate storage conditions.
Defective product labelling.
Failure to communicate safety risks.
Russian legal responsibility may arise under several provisions:
Civil Code Article 1064: General liability for causing harm.
Civil Code Article 1095: Liability for harm caused by defects in goods, work or services.
Civil Code Article 1096: Persons responsible for compensation for harm caused by defects.
Federal Law No. 61-FZ: Regulatory responsibilities relating to medicinal-product quality and safety.
For example, if a recombinant therapeutic protein becomes contaminated during manufacturing and causes patient injury, the manufacturer may face regulatory investigation and civil liability, depending on the facts and applicable legal requirements.
13. Environmental protection and biosafety
Recombinant protein manufacturing frequently involves genetically modified microorganisms.
The law therefore requires attention to biological containment and risk management.
Important considerations include:
Containment of genetically modified production organisms.
Prevention of accidental environmental release.
Appropriate biological and physical safety arrangements.
Risk assessment of production activities.
Safe disposal of biological waste.
Protection of employees.
Monitoring of relevant environmental risks.
Article 7 of Federal Law No. 86-FZ establishes a safety framework that includes risk levels for genetic-engineering activities.
The distinction between contained laboratory or industrial operations and deliberate environmental release is essential.
ГАРАНТ+1
14. Major legal challenges in Russian recombinant protein biotechnology
| Legal challenge | Explanation |
|---|---|
| Patent ownership | Determining ownership of engineered proteins and production technologies |
| Biosimilar competition | Establishing scientific similarity to reference medicines |
| Manufacturing quality | Maintaining GMP compliance |
| Scientific disclosure | Providing adequate patent descriptions |
| GMO containment | Preventing unintended environmental release |
| Clinical evidence | Establishing safety and therapeutic effectiveness |
| Product liability | Addressing injuries caused by defective biological medicines |
| Technology transfer | Protecting confidential manufacturing technology |
| Regulatory compliance | Obtaining appropriate marketing authorisation |
| International trade | Complying with applicable EAEU and importing-country requirements |
15. Practical example: Legal regulation of recombinant human insulin
Consider a Russian biotechnology company developing recombinant human insulin.
GEROPHARM production site in Obolensk | GEROPHARM
Optimized fed-batch fermentation: A cost-effective, scalable solution
Purification/Downstream processing
9
The company introduces a human insulin gene into an appropriate microbial production system.
The following legal requirements become relevant:
Stage 1 – Research and development
Federal Law No. 86-FZ applies to relevant genetic-engineering activities.
Stage 2 – Production strain protection
The company may apply for a patent protecting a novel production strain or technical production process under Part IV of the Civil Code.
Stage 3 – Manufacturing
The manufacturer must comply with applicable EAEU GMP requirements under Decision No. 77.
Stage 4 – Protein purification and quality assessment
The insulin must undergo appropriate identity, purity, potency, stability and contamination testing.
Stage 5 – Clinical and regulatory assessment
The manufacturer must satisfy applicable preclinical, clinical and medicinal-product registration requirements.
Stage 6 – Commercial distribution
The product may be marketed only after obtaining the required authorisation and satisfying applicable distribution and pharmacovigilance requirements.
Stage 7 – Patent and product liability
The manufacturer must respect third-party patent rights and maintain systems for handling defective products and adverse reactions.
This example demonstrates how Russian pharmaceutical, biotechnology, patent and environmental laws operate together.
16. Conclusion
Biotechnology recombinant protein law in Russia is a multidisciplinary regulatory framework involving genetic engineering, pharmaceutical regulation, patent protection, manufacturing standards, environmental safety and consumer protection.
Federal Law No. 86-FZ regulates relevant genetic-engineering activities, while Federal Law No. 61-FZ governs the circulation of medicinal products. EAEU Decisions Nos. 77, 78 and 89 provide important common requirements concerning manufacturing, registration and assessment of biological medicines.
The GEROPHARM recombinant insulin-related patent proceeding is particularly significant because it demonstrates the legal importance of technical disclosure, industrial applicability and scientific evidence in protecting recombinant protein production technology.
The Supreme Court's 2023 GMO decision additionally illustrates the consequences of violating applicable genetic-engineering registration requirements.
Ultimately, Russian law seeks to ensure that recombinant protein technology can be developed and commercialised while maintaining scientific reliability, patient safety, environmental protection and legitimate intellectual property rights.
17. Important legal references for further research
Federal Law No. 86-FZ of 5 July 1996 – Genetic Engineering Activities.
Federal Law No. 61-FZ of 12 April 2010 – Circulation of Medicines.
Federal Law No. 323-FZ of 21 November 2011 – Protection of Public Health.
Russian Civil Code, Part IV – Intellectual Property.
EAEU Council Decision No. 77 of 3 November 2016 – Good Manufacturing Practice.
EAEU Council Decision No. 78 of 3 November 2016 – Registration and Examination of Medicines.
EAEU Council Decision No. 89 of 3 November 2016 – Assessment of Biological Medicines.
Russian Supreme Court Decision No. 9-АД23-12-К1 of 19 September 2023.
Rospatent proceeding concerning Russian Patent No. 2807548, approved 13 October 2025.
Moscow Arbitration Court Case No. A40-71471/2017 – Nativa v. Celgene.
Primary legal research sources
Russian Federal Law No. 61-FZ – Medicines
Russian Federal Law No. 86-FZ – Genetic Engineering
Rospatent – GEROPHARM recombinant insulin patent proceeding
Supreme Court GMO decision, 2023
Academic note: This is a general legal research explanation, not a legal opinion on a particular company's regulatory status. The cited materials include both court judgments and administrative patent proceedings; they should not be treated as equivalent judicial precedents.

comments